Scilex Holding Co (SCLX)

Currency in USD
10.600
-0.290(-2.66%)
Closed·
10.6000.000(0.00%)
·
SCLX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
10.34511.120
52 wk Range
3.60034.270
Key Statistics
Prev. Close
10.6
Open
10.91
Day's Range
10.345-11.12
52 wk Range
3.6-34.27
Volume
57.82K
Average Volume (3m)
111.92K
1-Year Change
-31.1688%
Book Value / Share
-32.19
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SCLX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.000
Downside
-100.00%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Scilex Holding Co News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Scilex Holding Co Company Profile

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; and Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA. Scilex Holding Company is based in Palo Alto, California.

Employees
30

Compare SCLX to Peers and Sector

Metrics to compare
SCLX
Peers
Sector
Relationship
P/E Ratio
−0.2x−3.9x−0.6x
PEG Ratio
0.000.010.00
Price/Book
−0.4x−0.7x2.6x
Price / LTM Sales
1.6x2.0x3.4x
Upside (Analyst Target)
-156.7%42.5%
Fair Value Upside
Unlock5.7%5.8%Unlock

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 0.000
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
D. Boral Capital
Hold---Downgrade11/04/2025
D. Boral Capital
Buy22.00+107.55%-New Coverage27/01/2025

Earnings

Latest Release
Nov 14, 2025
EPS / Forecast
-22.17 / -0.12
Revenue / Forecast
10.56M / 30.00M
EPS Revisions
Last 90 days

SCLX Income Statement

People Also Watch

13.940
WVE
+0.87%
1.860
BEAT
-7.46%
18.080
VOR
+2.73%
3.3700
SIDU
-8.42%
12.650
SUPX
-6.57%

FAQ

What Is the Scilex Holding (SCLX) Stock Price Today?

The Scilex Holding stock price today is 10.600

What Stock Exchange Does Scilex Holding Trade On?

Scilex Holding is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Scilex Holding?

The stock symbol for Scilex Holding is "SCLX."

What Is the Scilex Holding Market Cap?

As of today, Scilex Holding market cap is 64.95M.

What Is Scilex Holding's Earnings Per Share (TTM)?

The Scilex Holding EPS (TTM) is -45.04.

From a Technical Analysis Perspective, Is SCLX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Scilex Holding Stock Split?

Scilex Holding has split 1 times.

How Many Employees Does Scilex Holding Have?

Scilex Holding has 30 employees.

What is the current trading status of Scilex Holding (SCLX)?

As of 21 Jan 2026, Scilex Holding (SCLX) is trading at a price of 10.600, with a previous close of 10.600. The stock has fluctuated within a day range of 10.345 to 11.120, while its 52-week range spans from 3.600 to 34.270.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.